Delaware Group Tax Free Fund has released its latest financial report, showcasing a strong asset base and a stable financial position. The report, filed with the SEC on October 29, 2026, highlights the fund's total assets amounting to over $1 billion, with net assets reported at approximately $1.07 billion. This update is crucial as it reflects the fund's ongoing performance in the competitive landscape of municipal bond investments.
Delaware Group Tax Free Fund operates as an investment entity, primarily focusing on tax-free municipal bonds. The fund is registered under the SEC Act of 1940 and has been a significant player in the investment sector. The fund's CIK is 0000728352, and it has a history of adapting to market changes to maintain its competitive edge.
According to the latest filing, the fund's total assets are reported at $1,091,602,673.26, with total liabilities of $25,218,578.09. This results in net assets of $1,066,384,095.17. The fund's financial health is further emphasized by its lack of short-term borrowing, indicating a stable investment strategy. The filing states, "Total assets reflect the fund's commitment to providing tax-free income to its investors." This statement underscores the fund's strategic focus on municipal bonds.
The financial report may impact various stakeholders, including investors, financial analysts, and competitors in the municipal bond market. Investors looking for stable, tax-free income options may find Delaware Group Tax Free Fund appealing, especially given its substantial asset base and lack of liabilities. Additionally, competitors in the investment sector will likely analyze this report to gauge the fund's performance relative to their offerings.
Looking ahead, Delaware Group Tax Free Fund may continue to file updates as it navigates the investment landscape. The filing does not specify what actions will follow this report, but it is expected that the fund will maintain its focus on optimizing its portfolio and providing value to its investors.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






